We and others have shown that inhibition of mTORC1 relieves negative feedback on upstream activators, including IRS-1, IGF-1R, human epidermal growth factor receptor 3 (HER3), and PI3K, which may subsequently promote cell survival and antagonize the anti-cancer effects of mTORC1 inhibitors [18–21]. The gene discussed is IGF1R; the disease is cancer.